At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 245 enrolled
Drug / intervention
Buprenorphinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of NORSPAN® (Buprenorphine) in Korean Patients With Spinal Disorders (NOBLE)
In Brief
A Phase 4 clinical trial evaluating Buprenorphine for Spinal Disorder. Completed, enrolled 245 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the pain reduction rate after 8 weeks treatment of NORSPAN® from baseline. And secondary purpose are: pain reduction rate after 4 weeks treatment from baseline(week 0) the EQ-5D, the pain and sleep questionnaire, physician's overall satisfaction subject's overall satisfaction, and safety
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Disorder
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedMar 2013
Primary CompletionJun 2013
TodayJul 2026
First PostedMar 26, 2013
Enrollment StartSep 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.3 years ago
Interventions
Buprenorphinedrug
8weeks treatment with Norspan®(Buprenorphine)